The effect of captopril on definitive patients with coronavirus pneumonia

Evaluation the effect of captopril in the treatment of definitive patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140824018915N9

Enrollment

Registered

2021-06-04

Start date

2021-06-05

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus pneumonia. This code assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing

Interventions

Intervention 1: Intervention group: In addition to the usual treatment regimen, patients receive captopril at a dose of one 25 mg tablet every 8 hours for 2 weeks from the start of treatment. Interven

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COVID-19 disease confirmed by imaging (HRCT) or Real Time PCR

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Bilateral renal artery stenosis Hereditary angioedema Psoriasis

Design outcomes

Primary

Measure	Time frame
Percentage of oxygen secretion. Timepoint: At the beginning of the study (before the intervention) and 14 days after the start of taking captopril. Method of measurement: Using a pulse oximeter.;Mortality rate. Timepoint: At the end of hospitalization of patients. Method of measurement: According to the physician report.;Duration of hospitalization. Timepoint: At the end of hospitalization of patients. Method of measurement: Calculated by the physician.	—

Measure

Time frame

Percentage of oxygen secretion. Timepoint: At the beginning of the study (before the intervention) and 14 days after the start of taking captopril. Method of measurement: Using a pulse oximeter.;Mortality rate. Timepoint: At the end of hospitalization of patients. Method of measurement: According to the physician report.;Duration of hospitalization. Timepoint: At the end of hospitalization of patients. Method of measurement: Calculated by the physician.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMousalreza Hoseini

Mashhad University of Medical Sciences

hoseinimr@mums.ac.ir+98 51 3801 2742

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026